Evidence map›Paper›PMID 26416275›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.

Amir Horowitz, Lisbeth A Guethlein, Neda Nemat-Gorgani, Paul J Norman, Sarah Cooley, Jeffrey S Miller, Peter Parham

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Virus-specific NK cell memory.The Journal of experimental medicine · 2021
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Memory responses of natural killer cells.Seminars in immunology · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amir HorowitzDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305; Stanford Immunology, Stanford University School of Medicine, Stanford, CA 94305; and.
Lisbeth A GuethleinDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305;
Neda Nemat-GorganiDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305;
Paul J NormanDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305;
Sarah CooleyDepartment of Hematology, Oncology, and Transplantation, School of Public Health, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.
Jeffrey S MillerDepartment of Hematology, Oncology, and Transplantation, School of Public Health, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.
Peter ParhamDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305; Stanford Immunology, Stanford University School of Medicine, Stanford, CA 94305; and peropa@stanford.edu.
Stanford University · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Viral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2M
INTERACTIONS BETWEEN HLA CLASS I &CYTOLYTIC LYMPHOCYTESR01AI022039 · NIAID · STANFORD UNIVERSITY · PI PARHAM, PETER R · 1985 to 2017
$5.2M
Inducing NK cells to remember and fight cancerR01HL122216 · NHLBI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2018
$1.5M
CyTOFS10OD016318 · OD · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2013 to 2013
$600k
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA077598NCI NIH HHS R35 CA197292NHLBI NIH HHS R01 HL122216NIAID NIH HHS R01 AI022039NIAID NIH HHS R01 AI22039NIH HHS S10OD016318-01PHS HHS P01 65493
6 · The paper itself

Abstract

Mass cytometry was used to investigate the effect of CMV reactivation on lymphocyte reconstitution in hematopoietic cell transplant patients. For eight transplant recipients (four CMV negative and four CMV positive), we studied PBMCs obtained 6 mo after unrelated donor hematopoietic cell transplantation (HCT). Forty cell-surface markers, distinguishing all major leukocyte populations in PBMC, were analyzed with mass cytometry. This group included 34 NK cell markers. Compared with healthy controls, transplant recipients had higher HLA-C expression on CD56(-)CD16(+) NK cells, B cells, CD33(bright) myeloid cells, and CD4CD8 T cells. The increase in HLA-C expression was greater for CMV-positive HCT recipients than for CMV negative recipients. Present in CMV-positive HCT recipients, but not in CMV-negative HCT recipients or controls, is a population of killer cell Ig-like receptor (KIR)-expressing CD8 T cells not previously described. These CD8 T cells coexpress CD56, CD57, and NKG2C. The HCT recipients also have a population of CD57(+)NKG2A(+) NK cells that preferentially express KIR2DL1. An inverse correlation was observed between the frequencies of CD57(+)NKG2C(+) NK cells and CD57(+)NKG2A(+) NK cells. Although CD57(+)NKG2A(+) NK cells are less abundant in CMV-positive recipients, their phenotype is of a more activated cell than the CD57(+)NKG2A(+) NK cells of controls and CMV-negative HCT recipients. These data demonstrate that HCT and CMV reactivation are associated with an increased expression of HLA-C. This could influence NK cell education during lymphocyte reconstitution. The increased inhibitory KIR expression by proliferating CMV-specific CD8 T cells suggests regulatory interactions between HLA-C and KIR might promote Graft-versus-Leukemia effects following transplantation.

Indexed as

Acute DiseaseCD57 AntigensCD8-Positive T-LymphocytesCell Line, TumorCells, CulturedCytomegalovirusCytomegalovirus InfectionsFlow CytometryGenotypeHematopoietic Stem Cell TransplantationHLA-C AntigensHost-Pathogen InteractionsHumansK562 CellsKiller Cells, NaturalLeukemia, MyeloidCD57 AntigensHLA-C AntigensKIR2DL1 protein, humanKLRC2 protein, humanNK Cell Lectin-Like Receptor Subfamily CReceptors, KIR2DL1

Identifiers

PMID26416275
PMCPMC4610859
OpenAlexW2249411482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.